IL6 and neoplasm: CD19/CD22 dual-target CAR T is more likely to target tumor cells with high CD22 expression, reduce overkill of normal B-cells, and thus reduce the total amount of systemic inflammatory factors (such as IL-6, IFN-γ) released (53).